New agents and therapies in prostate cancer, as in other diseases, need to be accurately, comprehensively and logically developed. The golden standard, a prospective, randomised phase III study can only be carried out ef®ciently if phase I and phase II studies have been completed. The advent of new therapies which will be used in early stage disease, necessitates the development of new methods of measuring their activity and correlating it with an in¯uence on the natural history of the disease. Efforts to get results more quickly by using weaker endpoints and retrospectively carrying out metanalyses have their disadvantages and dangers.
Introduction
The need to carry out good and reliable investigations to de®ne the best management strategy for the different stages of prostate cancer remains. The best way to investigate any new agent, and particularly any new anti cancer agent is by means of randomised phase III clinical trials. It is surprising that prostate cancer remains almost the only cancer where there has never been a randomised clinical trial carried out to fully investigate the only methods available to us to cure the disease. Although the incidence of prostate cancer has fallen since 1994 in the USA 1 and is beginning to fall elsewhere, it is still clear that it will remain possibly the most commonly diagnosed cancer in Europe for some time to come and there remains a need to improve our therapeutic options. Some of the problems in the interpretation of the results of prostate cancer trials are the following.
Ever since the characterisation of PSA in 1979, 2 clinicians have had a tool which can monitor progress and remission in newly diagnosed prostate cancer extremely accurately. In the later stages of the disease however, there are still problems over the accuracy of this measurement and even the speci®city of this particular antigen. 3 Furthermore, because the majority of metastatic lesions from cancer of the prostate occur in bone, objective measurement of progression and the effect of speci®c anti-cancer therapy remain dif®cult. In early stage disease the presence of latent prostate cancer, found in patients undergoing TUR for benign disease, leads to a risk that such patients, in whom their prostate cancer will never pose a threat, may be included in trials of active therapy. Because the majority of patients over the age of 80 will have a focus of prostate cancer which will never prove life limiting, the inclusion of these patients in treatment studies of localised prostate cancer should be stopped. In trials of therapeutic interventions in early prostate cancer an age limit of 70 y should be set to avoid the inclusion of too many patients where the diagnosis of prostate cancer is irrelevant to their anticipated life-span and the quality of their remaining years.
Finally, many of the new agents are only likely to be effective at a certain stage of the disease. In order not to miss this activity these agents should not routinely be tested in measurable metastatic disease. Methods need to be found to investigate their activity at the stage of the disease where they might be effective.
Type of trials
Clinical trials are often divided into early and late, Phase I and phase II studies being included in the ®rst, comparative phase II, phase III and phase IV studies included in the second group. In order to improve the ef®cacy and ef®ciency of clinical trialling, in any cancer, it is of vital importance that all people involved in the development of a therapy should cooperate in the various trials stages. It is only if the number of patients needed to assess a drug in a phase III study is known that the best phase II studies can be carried out. Although phase II studies may give an indication that the given agent is effective against a particular tumour, such as prostate cancer, it is only by means of good prospective randomised phase III studies, that the role for the drug in the disease can be proven.
Although good clinical practice is of®cially de®ned as à guideline', the majority of trialling organisations now insist that it is adhered to in all their studies. In prostate cancer trials, one important aspect which has led to some recent dif®culties, is the amount of information that the patient must receive about the disease and about the trial itself. This has led to two changes in some recent trials, the ®rst being that the trial has been simpli®ed as much as possible to make certain that the patient can understand therefore exactly what treatment he is going to receive and that therefore the written informed consent, now insisted on in the majority of centres, can be accurately complied with. A second, rather less important problem, is that because of the necessity of explaining every conceivable, possible side-effect that may occur from a given therapy, blinding of studies, particularly involving hormonal therapy, has become almost impossible. If the patient realises that a tingling in his nipples is a side-effect of the non-steroidal anti-androgen 5 which is one arm of a so-called blinded study, then further compliance in the study may be extremely dif®cult and the subjective and objective assessments of both doctor and patient may be impared.
Randomisation and informed consent
Randomisation must be arbitrary and carried out at a distance from those closely involved with the operation of the trial. In very large trials patients are randomised between 2 or 3, or more treatments, in such a way that it is hoped by the end of the recruitment the different arms are equally balanced for important prognostic factors. However, this is not always so and therefore it is frequently necessary to carry out a multi variate analysis in order to compensate for any discrepancies. The hazard of this technique is that in each group the numbers may be too small to detect the difference being sought and indeed a small difference in outcome can easily be missed. An extra technique called minimisation can prevent this. By this technique the person responsible for randomisation examines every single patient admitted to the trial and can allocate that patient to one or other treatment group to ensure that the balance of all factors which could possibly in¯uence the outcome of the study is maintained between the different groups. 6 The necessity for and sometimes dif®culty in obtaining written informed consent has been mentioned above. Where a new compound is being compared to standard therapy, Zelen 7 has suggested that only for the patients allocated to the investigational agent is written consent necessary since without the trial patients would receive standard therapy anyway. This technique of seeking consent after randomisation has been employed in some prostate cancer studies. Another technique employed in a study in the timing of hormonal therapy in node positive localised disease (EORTC protocol 30846, study coordinator prof. Schro È der, Rotterdam), allowed the patient to choose when he started therapy. When randomisation is very dif®cult and threatens the continuance or indeed existence of a study which is important, one of these methods may be used, but the limitations must be de®ned.
Early trials in prostate cancer
The classical development of a new anti cancer drug involving its use in phase I, early phase II and late phase II studies is seldom possible in drugs hopefully effective in the treatment of prostate cancer. Prostate cancer patients are rarely suitable for inclusion in phase I studies because of their age, the absence of measurable cancer metastases and their lack of bone marrow reserve because of bony secondary deposits. Novel therapies such as cytotoxic agents, antimetastatic agents, anti growth factor agents such as Suramin are generally tested in very advanced disease where patients have measurable soft tissue metastases after hormonal therapy. This group of patients is small and the interpretation of the results of phase II studies in them is often proved to be incorrect when these compounds have come into phase III studies. For instance Mitomycin C in a phase II study in measurable metastatic disease, carried out by the EORTC (30804), gave a partial response rate of 29%. When the same compound was tested against Estracyt in a phase III study (30865) it was found to be minimally effective and associated with considerable toxicity.
As mentioned earlier, the development of novel treatments in prostate cancer demands that a method of measuring their effectiveness needs to be developed at the stage of the disease where they are likely to be most effective. For instance the use of anti-angiogenesis, anti mitotic, anti invasive drugs will only be assessed effectively in early stage disease. At this time we have very poor methods of assessing the effectiveness of these compounds in localised disease. The use of PSA as a surrogate in metastatic disease has been proven but in localised, as was shown by Eisenberger et al, 8 PSA is most unreliable and where there is no direct cytotoxic effect of a new compound, changes in its level may not re¯ect activity of that compound in preventing spread of the prostate cancer 8 (Table 1) .
In testing these new compounds, either histological parameters or cytological and molecular markers must be used as a measure of activity. For instance in testing anti-angiogenesis agents, patients who are suitable for radical prostatectomy may be given the agents for 4 ± 6 weeks, prior to radical prostatectomy, to assess their effectiveness. While this measure will be appropriate in a phase II study, in a comparative study the patients who might be randomised to the placebo arm will be extremely dif®cult to recruit.
In patients with more advanced disease, either locally advanced or metastatic, not suitable for curative therapy, the investigation of new hormonal and combination hormonal and cytotoxic agents has largely been carried out in open phase II studies, with clearly de®ned stopping rules. The investigation of a new, non-steroidal antiandrogen, bicalutamide, has been carried out in such a manner. Dose ranging studies were ®rst carried out on patients with localised disease, with a raised PSA, or metastatic disease and because the effectiveness of this agent had not been tried out in measurable metastatic disease, patients came off study following biochemical progression or if they experienced treatment failure, for a variety of reasons. Clearly, objective progression and survival were also endpoints. The study of bicalutamide could well serve as an example for the future developments of hormonal therapies in prostate cancer although many criticisms have been made over the use of PSA progression as one of the indications for treatment failure. Using time to treatment failure as a main endpoint ensures that patients could be offered an alternative therapy at their own request, or if in the opinion of the investigator there was already present, or at least a danger of signi®cant disease progression. There are a number of major problems with this approach.
The level of PSA in locally advanced or metastatic disease may be in¯uenced not only by progression or remission of the disease state but also by the ability of a hormonal treatment to alter the expression of PSA by carcinoma cells. Furthermore, time to treatment failure includes withdrawal of the study at a patient's request, which may be unassociated with disease related symptoms or signs, or at the physician's request who may consider that the agent is giving unacceptable side effects with minimal evidence of clinical ef®cacy. Side effects themselves, which may clinically be minor, but subjectively important, will also lead to the withdrawal of patients from these studies.
In phase II studies of new agents in prostatic cancer, it is important to look for meaningful surrogate endpoints. In patients progressing after hormonal therapy, where cytotoxic agents, or cytostatic agents may be indicated, the use of PSA as a surrogate endpoint can only be con®rmed if all patients are followed for survival or time to further progression. In this group of patients it is vitally important that all parameters such as haemoglobin, weight, quality of life, PSA, alkaline phosphatase and ESR are measured in order to determine which of these surrogate endpoints correlate with progression and survival. In phase II studies of agents suitable to be used in early stage disease, histological, cytological and molecular studies need to be also linked to later evidence of objective progression and survival, in order to ascertain which of the surrogate endpoints correlates with a signi®cant effect on disease progression.
Late studies in prostate cancer
Although phase III studies remain the golden standard for the assessment of the ef®cacy of a new compound in prostate cancer, randomised phase II studies may also have a role to play. 9 A randomised phase II study is in effect the carrying out of two phase II studies of different or related compounds that are believed to be effective in prostatic cancer. It is in no way a comparative study. In many situations it can be used to assess the effectiveness of two different doses of the same compound, or to compare an effective compound with an analogue. In randomised phase II studies, particularly investigating the activity of a compound and an analogue, the response rate may be the same, but the side effect pro®le may be markedly different, thereby suggesting which of the two compounds would be appropriate for a phase III study. 10 In a recent randomised phase II study, carried out by the EORTC of Estracyt vs Estracyt and Vinblastine, the ef®-cacy of both regimes was minimal as measured by PSA response. The side effect pro®le of both combination arms was very signi®cant and therefore it was decided not to proceed to a phase III study with either of these agents. Because the treatment withdrawals due to progression and toxicity outnumbered the responses there was no indication to proceed to a phase III study.
No phase III studies have been performed comparing curative therapies in early prostate cancer. Therefore the following comments refer exclusively to those performed in advanced disease.
Phase III studies of new agents in prostate cancer are the only studies whereby superiority of a new therapy over standard therapy may be satisfactory demonstrated. In both localised and advanced prostatic cancer, superiority of any new therapy is likely to be marginal, the reason that these studies require large numbers of patients.
The power of a study is related to the chance that an effective or more effective agent will be missed, the socalled type II error or that a treatment will be deemed effective, or more effective than standard therapy, when infact it is not (Type I error). These factors are clearly related to the number of patients in a study, therefore, particularly, if the advantage of any new therapy is going to be small, very large numbers of patients need to be included. In early stage prostate cancer, because of the indolent nature of the disease, many studies will need to be followed for 10 or even 15 y to show that one or other therapeutic manoeuvre is the most effective. Such large studies are often dif®cult to recruit and can only be done in large national or international trialling organisations. This means that in order to maintain a reasonable quality of data, the trial needs to be extremely simple and probably only try to answer one, or at the most two questions.
One such recently reported study was carried out by the MRC in the UK and although hailed as a landmark study by some it has also been criticised by others. This study of immediate or deferred orchiectomy, or LHRHagonist therapy, in asymptomatic patients, with any stage of non curable prostate cancer, recruited nearly 1000 patients in a relatively short space of time and had the merit that clinicians did not have to alter their daily practice in order to include patients in the study. Although this improved recruitment, it led to a number of patients dying before they received any therapy for prostate cancer because the follow-up intervals were so long and also to dif®cult statistical interpretation of results caused by the very wide spectrum of patients included and sometimes lack of accuracy of de®nition of endpoints by individual clinicians. The major advantage of the study was however, that clinicians who wished to, could include very large numbers of their patients and therefore the spectrum of patients included in the study re¯ected daily practice more than in some other studies. 11 To a certain extent many phase III studies of advanced prostate cancer have been overtaken by subsequent results of basic science. Two examples are the following.
A greater understanding of the selectivity and sensitivity of androgen receptors for naturally occurring androgens and receptor antagonists can explain the apparent failure of androgen receptor antagonists in the treatment of widespread disease. Based on the molecular action of the antagonists, frequently called anti-androgens, it seems unlikely that the receptor antagonist could be given in high enough doses to block all the receptors in a patient with widespread metastatic disease, without giving rise to signi®cant toxicity. Furthermore, in a case of a non-steroidal receptor antagonist, there may be a surge of testosterone which, because of its more powerful attraction to the androgen receptor, may well unseat the antagonist and stimulate the cancer cell. 12 Recently LHRH-agonists have been shown to have possibly additional effects to their inhibition of the production of LHRH and therefore testosterone. 13 If indeed this is proven to be the case then the differences attributed to anti-androgens in studies of combined androgen blockade, using LHRH-agonist and anti-androgen against surgical castration may be¯awed in that the difference is not due to the addition of an anti-androgen but to a difference between surgical and medical castration. Hopefully, closer cooperation between clinicians and basic scientists and the better application of their collective knowledge on the mechanism of hormonal and other growth factors actions will lead to better and more logical trial design in the future.
Although the performance of large randomised phase III trials remains the trialist's goal and the statistician's dream, there are a number of methods for gaining useful information from smaller individual trials.
It is possible to carry out meaningful phase III studies, comparing two different therapies such as the recently completed EORTC study (30892) comparing cyproterone acetate and¯utamide, with relatively small numbers of patients by clearly de®ning prognostic factors. These agents were investigated in patients with symptomless, metastatic disease, with good prognostic factors and some degree of sexual activity. Although it is unlikely that a therapeutic bene®t for one or other of these agents will be demonstrated, there had been considerable interest in the differing side-effect pro®les in this clearly de®ned group of patients. Because the number of patients suitable for inclusion is limited, this study took nearly 8 y to complete and also its results will not be interpretable over the whole range of patients with prostate cancer seen in the average urological practice.
However, if there is no difference in ef®cacy but the sideeffect pro®le is markedly different then this information can be used when these agents are employed in different patient groups, such as those with non-metastatic but locally advanced disease. 14 A second method of limiting the number of patients needed to answer a given question, is to look for the demonstration of equivalence of two compounds instead of trying to demonstrate that one is superior to the other. This is important when comparing two treatments that have markedly different side-effect pro®les. Depending on the statistical analysis employed, it is, however, possible to miss a difference in ef®cacy of as much as 25%, if patient numbers are too limited.
A third method of avoiding the carrying out of single, large studies is to perform a metanalysis of similar studies comparing similar therapies. The metanalysis recently carried out by the Prostate Cancer Triallists Collaborative Group has looked at 25 studies comparing some form of maximal androgen blockade against simple medical or surgical castration which included nearly 8000 patients and where over 2 out of 3 of the patients have died. 15 The metanalysis is an analysis of survival over all these studies and although there appears to be no statistical difference in favour of maximal androgen blockade at this time, there is considerable dispute and debate as to whether a clinical bene®t for MAB has been demonstrated in a subset of patients. One principle of metanalysis is that the trials must be really similar. The principal endpoints should be the same and the trials should be carried out in roughly the same group of patients. The trials must also be individually statistically sound to answer their principal objective. The trials included in the metanalysis should also be roughly of the same maturity. This particular metanalysis suffers from the basic problem that not all the trials included were of the same duration nor indeed did they all have survival as a principal endpoint. Many of the studies were aimed at showing objective or subjective response and survival has only been examined retrospectively and may have been in¯uenced by other therapeutic measures. Metanalysis is probably something which needs to be planned for before any of the component studies are started, in order to avoid the dif®culties which have occured with the Prostate Cancer Triallists Collaborative Group studies. 16 A recent promising development has been the acceptance of a difference in quality of life parameters in patients with hormone refractory disease in a trial of Mitoxantrone and prednisone vs prednisone alone for registration of the combination by the FDA. 17 This means an acceptance of improvements in the quality of life in these patients as a worthwhile treatment objective. It also gives another yardstick for the investigation of new compounds in hormone refractory disease.
Phase IV trials
Phase IV studies in the investigation of new agents in the treatment of cancer are either cost-effectivity studies or studies investigating patient acceptability of new therapeutic strategies. Although many of these studies only involve completion of quality of life questionnaires and patient's preference questionnaires, they nevertheless are clinical trials and as such need to be monitored by ethics committees and data monitoring committees.
Clinicians treating advanced prostate cancer are faced with many dilemmas. Not only are many hormonal therapies extremely expensive, such as maximal androgen blockade, costing around 2500 dollars a month, but many of the cheaper therapies such as surgical castration or the use of oestrogens have signi®cant, longterm sideeffects which make the saving of money of only relative importance. With the introduction of intermittent therapy, quality of life issues are assuming an even greater role in phase III and phase IV studies.
The role of new therapies in the treatment of prostate cancer Table 2 includes a list of the new therapies at present being investigated in the treatment of prostate cancer.
Since many of the agents, such as anti-angiogenesis and anti-metastatic agents, will probably ®nd a place in the treatment of early stage disease, as mentioned earlier, we need to continue the search for useful, molecular markers of activity and for histological parameters which can be investigated in patients prior to radical prostatectomy which will tell us whether or not these agents are effective in early stage disease. Unfortunately, PSA appears to be becoming less speci®c the more we know about it and clearly the development of other markers such as PSMA, HK2 and proliferation markers, such as Ki67, may well have a useful role in the future. Unfortunately, even PMSA has recently been shown to be produced by other organs than the prostate, such as the duodenum and the small bowel in patients with coeliac disease. 18 
Conclusions
The investigation of new agents via clinical trials in prostatic cancer has a very checquered history. Unfortunately, it seems that a prospective, multi centre, randomised trial of de®nitive, curative therapy, either radiotherapy or surgery, will never be carried out. A large number of new agents appearing for the treatment of prostate cancer are unlikely to be effective in measurable disease, where they are currently being tested. New methods of identifying a signi®cant effect of these new therapeutic options in early stage disease need to be developed.
Above all, closer co-operation between basic scientists, clinicians and statistiticians from the beginning of the development of a new therapy is essential if clinical trials in prostate cancer are going to answer the important questions in a reproducible and reliable manner. Clinical trials in prostatic cancer DWW Newling
